These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38600160)

  • 1. Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer.
    Kim JS; Lee J; Nguyen TT; Choi SY
    Sci Rep; 2024 Apr; 14(1):8440. PubMed ID: 38600160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
    Miyake M; Nishimura N; Nishioka Y; Fujii T; Oda Y; Miyamoto T; Tomizawa M; Shimizu T; Owari T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Imamura T; Fujimoto K
    Int Urol Nephrol; 2024 Mar; 56(3):827-837. PubMed ID: 37910382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive studies may have potential to replace cystoscopy in non-muscle invasive bladder cancer follow-up.
    Lee J; Heo JE; Kang SK; Lee KS; Han H; Jang WS; Choi YD
    Sci Rep; 2022 Dec; 12(1):21677. PubMed ID: 36522359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Optimal surveillance intensity of cystoscopy in intermediate-risk non-muscle invasive bladder cancer].
    Wang F; Qin CP; DU YQ; Liu SJ; Li Q; Xu T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):669-673. PubMed ID: 35950390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.
    Rolevich AI; Zhegalik AG; Mokhort AA; Minich AA; Vasilevich VY; Polyakov SL; Krasny SA; Sukonko OG
    World J Urol; 2017 May; 35(5):745-752. PubMed ID: 27604374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer.
    Schroeck FR; Lynch KE; Li Z; MacKenzie TA; Han DS; Seigne JD; Robertson DJ; Sirovich B; Goodney PP
    Cancer; 2019 Sep; 125(18):3147-3154. PubMed ID: 31120559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis.
    Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; von Deimling M; Bianchi A; Pallauf M; Majdoub M; Pradere B; Abufaraj M; Moschini M; Karakiewicz PI; Iwatani K; Miki J; Kimura T; Shariat SF
    BJU Int; 2023 Jun; 131(6):643-659. PubMed ID: 36479820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
    Karaoglu I; van der Heijden AG; Witjes JA
    World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
    Rezaee ME; Lynch KE; Li Z; MacKenzie TA; Seigne JD; Robertson DJ; Sirovich B; Goodney PP; Schroeck FR
    PLoS One; 2020; 15(3):e0230417. PubMed ID: 32203532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of the COVID19 pandemic on the need and timing of second transurethral bladder tumour resection in high-grade non-muscle invasive bladder cancer.
    Vanneste M; van der Heij B; Christiaansen CE; Berendsen CL; Driessen EJM; Bruins HM
    World J Urol; 2023 Aug; 41(8):2173-2178. PubMed ID: 37328699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How Long Is Cystoscopic Surveillance Necessary?
    Ma J; Roumiguie M; Hayashi T; Kohada Y; Zlotta AR; Lévy S; Matsumoto T; Sano T; Black PC
    Eur Urol Focus; 2024 Jan; 10(1):189-196. PubMed ID: 37442722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.
    Sörenby A; Baseckas G; Bendahl PO; Brändstedt J; Håkansson U; Nilsson S; Patschan O; Tinzl M; Wokander M; Liedberg F; Gudjonsson S
    Scand J Urol; 2019; 53(2-3):109-115. PubMed ID: 31064253
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC).
    Datovo JCF; Neto WA; Mendonça GB; Andrade DL; Reis LO
    World J Urol; 2019 Oct; 37(10):2067-2071. PubMed ID: 30805685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer: 2-Year Follow-Up Outcomes.
    Li H; Wang L; Li H; Zhang P; Li Z; Xue L; Wang Z; Fu D; Chen Q; Luo Q; Chong T; Wang Z
    Oncology; 2024; 102(4):337-342. PubMed ID: 37647883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.